• Nuvalent will present preliminary dose-escalation data from the ALKOVE-1 Phase 1/2 trial of NVL-655, marking the first clinical disclosure for this next-generation ALK inhibitor.
• NVL-655 is designed to overcome key limitations of existing ALK inhibitors, including resistance mutations, poor brain penetrance, and CNS adverse events.
• The drug targets advanced ALK-positive non-small cell lung cancer and has been engineered to remain active against multiple resistance mutations including the challenging G1202R solvent front mutation.
• The presentation will occur at the 35th AACR-NCI-EORTC Symposium in Boston on October 13, 2023, with a planned conference call the same day.